Thomas Marsland

1.1k total citations
21 papers, 813 citations indexed

About

Thomas Marsland is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Economics and Econometrics. According to data from OpenAlex, Thomas Marsland has authored 21 papers receiving a total of 813 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 4 papers in Economics and Econometrics. Recurrent topics in Thomas Marsland's work include Lung Cancer Treatments and Mutations (8 papers), Lung Cancer Research Studies (6 papers) and Lung Cancer Diagnosis and Treatment (6 papers). Thomas Marsland is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Lung Cancer Research Studies (6 papers) and Lung Cancer Diagnosis and Treatment (6 papers). Thomas Marsland collaborates with scholars based in United States, Austria and Kenya. Thomas Marsland's co-authors include Andrew F. Giusti, Todd S. Crocenzi, John Pippen, Pamela B. Mangu, Sandra L. Wong, Cathy Eng, Yuman Fong, David Lu, Jerome Seidenfeld and Deborah Schrag and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Thomas Marsland

21 papers receiving 794 citations

Peers

Countries citing papers authored by Thomas Marsland

Since Specialization

Citations

This map shows the geographic impact of Thomas Marsland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Marsland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Marsland more than expected).

Fields of papers citing papers by Thomas Marsland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Marsland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Marsland. The network helps show where Thomas Marsland may publish in the future.

Co-authorship network of co-authors of Thomas Marsland

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Marsland. A scholar is included among the top collaborators of Thomas Marsland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Marsland. Thomas Marsland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	New Landscape: Physician Compensation 2020 ·JCO Oncology Practice ·Christian A. Thomas, (unknown), (unknown), (unknown), Linda D. Bosserman, Debra A. Patt, Dhimant Patel, Michael J. Diaz, Thomas Marsland, (unknown), Edward P. Balaban, Elizabeth Blanchard, Gregg E. Franklin, Rahul Seth, Andrew D. Norden	3
2	Circulating Tumor Cell Data: Integration with Imaging and Serum Tumor Markers for Metastatic Breast Cancer Patient Management 2014 ·Case Reports in Oncology ·Thomas Marsland, Eric R. Schuur	2
3	Biomarker Analyses from a Randomized, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab with or without Erlotinib as Maintenance Therapy for the Treatment of Advanced Non-Small-Cell Lung Cancer (ATLAS) 2014 ·Journal of Thoracic Oncology ·Fairooz F. Kabbinavar, Louis Fehrenbacher, John D. Hainsworth, (unknown), Bruce Kressel, Thomas Marsland, Taral Patel, Mark A. Rubin, Leonard A. White, James Chih‐Hsin Yang, Barbara Klughammer, Dawn Colburn, Vincent A. Miller, Bruce E. Johnson	13
4	The NCI Community Oncology Research Program: What Every Clinician Needs to Know 2013 ·American Society of Clinical Oncology Educational Book ·Worta McCaskill‐Stevens, Alan P. Lyss, (unknown), Thomas Marsland, Rogerio Lilenbaum	24
5	The NCI Community Oncology Research Program: What Every Clinician Needs to Know 2013 ·American Society of Clinical Oncology Educational Book ·Worta McCaskill‐Stevens, Alan P. Lyss, (unknown), Thomas Marsland, Rogerio Lilenbaum	20
6	Defining Value in Cancer Care: AVBCC 2013 Steering Committee Report. 2013 ·PubMed ·(unknown), (unknown), Linda D. Bosserman, James T. Kenney, Grant Lawless, Thomas Marsland, (unknown), (unknown), Kevin Knopf, (unknown), (unknown), (unknown), (unknown), (unknown), Jennifer L. Malin, (unknown), (unknown), (unknown), Lillie D. Shockney	2
7	Pemetrexed with or without Matuzumab as Second-Line Treatment for Patients with Stage IIIB/IV Non-small Cell Lung Cancer 2010 ·Journal of Thoracic Oncology ·Joan H. Schiller, Joachim von Pawel, Philipp Schütt, Rafat Ansari, Michael Thomas, Mansoor N. Saleh, Robert McCroskey, Wolfgang Pfeifer, Thomas Marsland, Goetz Kloecker, Martin Sebastian, Robert Pirker, Raffael Kurek, (unknown), Mark A. Socinski	45
8	Reducing Cancer Costs and Improving Quality Through Collaboration With Payers: A Proposal From the Florida Society of Clinical Oncology 2010 ·Journal of Oncology Practice ·Thomas Marsland, (unknown), (unknown), (unknown), (unknown), Kristen L. King	9
9	American Society of Clinical Oncology 2009 Clinical Evidence Review on Radiofrequency Ablation of Hepatic Metastases From Colorectal Cancer 2009 ·Journal of Clinical Oncology ·Sandra L. Wong, Pamela B. Mangu, Michael A. Choti, Todd S. Crocenzi, Gerald D. Dodd, Gary S. Dorfman, Cathy Eng, Yuman Fong, Andrew F. Giusti, David Lu, Thomas Marsland, (unknown), Graeme J. Poston, Deborah Schrag, Jerome Seidenfeld, Al B. Benson	313
10	Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced‐stage nonsmall cell lung cancer 2008 ·Cancer ·Chandra P. Belani, Marshall T. Schreeder, Ronald G. Steis, (unknown), Thomas Marsland, (unknown), Suresh S. Ramalingam	53
11	Topotecan: Weekly intravenous (IV) schedule similar to standard 5-day IV schedule as second-line therapy for relapsed small cell lung cancer (SCLC)—A Minnie Pearl Cancer Research Network phase II trial 2006 ·Journal of Clinical Oncology ·Dianna Shipley, John D. Hainsworth, David R. Spigel, J. R. Gray, John H. Barton, (unknown), Mauro Nicolau, Thomas Marsland, (unknown), F. Anthony Greco	12
12	Maintenance gefitinib (G) after chemoradiotherapy (CRT) in patients (pts) with unresectable stage IIIA/B non-small cell lung cancer (NSCLC): A phase II trial of the Minnie Pearl Cancer Research Network 2006 ·Journal of Clinical Oncology ·J. R. Gray, David R. Spigel, John D. Hainsworth, (unknown), James D. Peyton, Eric Raefsky, (unknown), Thomas Marsland, (unknown), F. Anthony Greco	1
13	Results of a Phase II Trial of Gemcitabine in Patients with Non–Small-Cell Lung Cancer and a Performance Status of 2 2005 ·Clinical Lung Cancer ·Marcus A. Neubauer, Craig H. Reynolds, (unknown), (unknown), Habib M. Ghaddar, Thomas Marsland, Lina Asmar	12
14	Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials 2004 ·Lung Cancer ·Thomas Marsland, (unknown), Myrna M. Khan, (unknown), Kristi A. Boehm, Lina Asmar	23
15	Phase II Study of Trastuzumab plus Gemcitabine in Chemotherapy-Pretreated Patients with Metastatic Breast Cancer 2004 ·Clinical Breast Cancer ·Joyce O’Shaughnessy, S. Vukelja, Thomas Marsland, (unknown), (unknown), John Pippen	73
16	Preliminary results of a phase II trial utilizing gemcitabine in patients with advanced non-small cell lung cancer and a performance status 2 2004 ·Journal of Clinical Oncology ·Marcus A. Neubauer, Craig H. Reynolds, (unknown), (unknown), (unknown), Habib M. Ghaddar, Thomas Marsland, Lina Asmar	2
17	Rituximab Induces High Response Rate and Prolonged Remission in Chronic Idiopathic Thrombocytopenic Purpura (ITP): A Retrospective Analysis. 2004 ·Blood ·(unknown), (unknown), (unknown), (unknown), Joseph W. Sullivan, Thomas Marsland, Shalin Shah, Troy H. Guthrie	3
18	Pegylated Liposomal Doxorubicin as Single-Agent Treatment of Low-Grade Non-Hodgkin's Lymphoma: A Phase II Multicenter Study 2003 ·Clinical Lymphoma ·(unknown), Myrna M. Khan, Shaker R. Dakhil, (unknown), Thomas Marsland, Ralph E. Weinstein, (unknown), Lina Asmar	8
19	Phase II Trial of Gemcitabine plus Trastuzumab in Metastatic Breast Cancer Patients Previously Treated with Chemotherapy: Preliminary Results 2002 ·Clinical Breast Cancer ·Joyce O’Shaughnessy, Svetislava J. Vukelja, Thomas Marsland, (unknown), (unknown), John Pippen	45
20	Estrogen receptor status and response to chemotherapy in advanced breast cancer: The tufts-shattuck-pondville experience 1980 ·Cancer ·Charles Rosenbaum, Thomas Marsland, Leo L. Stolbach, Shanthi Raam, Joseph L. Cohen	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact